--- title: 'Funding Daily Summary: What Happened on October 30, 2026' headline: Dren Bio raises $350 million for dibotatug and its pipeline description: Aspen and Bambusa closed IPOs, Corxel pursued a SPAC transaction, and Capital Dynamics invested in an Italian healthcare platform. url: https://thebench.bio/news/funding/2026-10-30 topic: funding date: '2026-10-30' covers: - '2026-10-30' date_published: '2026-10-30T12:02:54Z' date_modified: '2026-10-30T12:02:54Z' tags: - Funding - Industry sources: 5 publisher: TheBench.Bio --- # Funding Daily Summary: What Happened on October 30, 2026 **Dren Bio raises $350 million for dibotatug and its pipeline** Aspen and Bambusa closed IPOs, Corxel pursued a SPAC transaction, and Capital Dynamics invested in an Italian healthcare platform. ## Today in brief Dren Bio raised $350 million in a private financing co-led by Juvia Group and Lightspeed Venture Partners to advance its cancer drug dibotatug and fund research across its pipeline. [1] [2] More than 300 people have received dibotatug in an ongoing Phase I/II study for two rare blood cancers. [2] Aspen and Bambusa closed IPOs, while Corxel took the SPAC route. [3] Capital Dynamics invested €14 million in Celsus Holding, which owns CareHub, to support the Italian platform’s expansion. [4] ## Dren Bio raises $350 million for dibotatug and pipeline research Dren Bio raised $350 million in a private financing co-led by Juvia Group and Lightspeed Venture Partners, its first disclosed venture round in more than four years. [1] [2] The company said it expects to use the proceeds to take dibotatug through late-stage clinical evaluation and regulatory submission, while funding research across several disease areas. [2] Dibotatug is a fully human antibody designed to bind CD94 and selectively eliminate disease-causing cytotoxic cells while sparing the broader immune system. [2] The drug is being studied for cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, neither of which has an approved therapy. [1] [2] More than 300 people with relapsed or refractory forms of the diseases have received dibotatug in an ongoing Phase I/II study. [2] Dren Bio plans to explore dibotatug in aplastic anemia, other bone marrow failure syndromes, and autoimmune conditions. [2] Juvia’s Sujal Shah and Lightspeed’s Shelley Chu joined Dren Bio’s board after the financing. [2] ## Also worth knowing - Aspen raised $140 million in an IPO to develop a cell therapy for Parkinson’s disease. [5] - CareHub has 31 multispecialty outpatient clinics in Italy, built through 20 acquisitions. [4] ## The day in numbers - **$350 million**: Dren Bio’s private financing, co-led by Juvia Group and Lightspeed Venture Partners. [1] [2] - **More than 300**: People treated with dibotatug in the ongoing Phase I/II study. [2] - **€14 million**: Capital Dynamics’ investment in CareHub’s holding company. [4] ## Also published - [Dren Bio pockets $350m for rare blood cancer programme](), pharmaphorum ## Sources 1. [Juvia, Lightspeed lead Dren’s $350M round as oncology program advances: Venture Report](), BioCentury, 2026-10-30 2. [Dren Bio raises $350m for dibotatug clinical development](), Pharmaceutical Technology, 2026-10-30 3. [Aspen, Bambusa close IPOs as Corxel takes SPAC route](), pharmaphorum, 2026-10-30 4. [Capital Dynamics invests €14m in Italian community healthcare platform CareHub](), Pharmafile, 2026-10-30 5. [Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s](), BioPharma Dive, 2026-10-30 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: